• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NeuroMetrix Inc. Highlights Recent Publication of Peer-Reviewed Journal Articles Related to NC-Stat System

Posted on: Wednesday, 10 January 2007, 12:00 CST

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the development and sale of proprietary products used to diagnose neuropathies and neurovascular disease, noted that in the past two months three new peer-reviewed journal articles have been published covering various aspects of the NC-stat System, providing further validation for the utility and accuracy of conventional nerve conduction studies performed with the NC-stat System.

In Jabre et al. (Physiological Measurements, January 2007), the validity of NC-stat lower extremity nerve measurements was assessed in 60 patients referred to a Veterans Administration electrodiagnostic laboratory. NC-stat and neurologist supervised measurements were highly correlated. The authors concluded "This study shows that the technology used by the NC-stat for studying the peroneal and posterior tibial nerves compares favorably .... with that obtained with traditional EMG equipment used under neurologist supervision."

In Vinik et al. (Diabetes Technology and Therapeutics, December 2006), the use of the NC-stat in 1,400 patients with diabetes in 28 primary care/endocrinology clinics was assessed in a prospective open-label study. The NC-stat identified nerve conduction abnormalities in 75% of patients, and over 50% had results suggestive of diabetic polyneuropathy (DPN). The NC-stat identified meaningful levels of neuropathy in patients within ADA recommended blood glucose control and in those newly diagnosed with diabetes. The authors concluded "[The NC-stat] can provide nerve conduction confirmation of DPN in primary care settings and has clinical utility. These findings have important implications for the clinical and epidemiological evaluation of DPN."

In Megerian et al. (Journal of the American Board of Family Medicine, January-February 2007) a retrospective blinded study of NC-stat utilization by 613 family medicine, primary care, and internal medicine ("FM/PCP/IM") physician practices was conducted. Over a two-week period 1,190 patients underwent nerve conduction studies ("NCS") for evaluation of carpal tunnel syndrome ("CTS"). The majority of patients were over 40, female, and overweight or obese. In 93% of studies, nerve selection followed published evidence-based guidelines. A total of 31% of tested limbs yielded normal results, 53% indicated CTS, and the remaining studies identified other neuropathies. The authors concluded "This study demonstrated that point-of-service NCS by FM/PCP/IM physicians for CTS was applied to appropriate patient subpopulations, was performed in accordance with evidence-based testing parameters, and generated relevant diagnostic outcomes."

Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, commented: "These studies add to the large and growing body of scientific literature supporting the accuracy and clinical utility of the NC-stat, which now exceeds 40 published papers, abstracts and posters. Furthermore, as is the case with other widely used nerve conduction and electromyography equipment, the NC-stat has FDA clearance under 21CFR890.1375 (diagnostic electromyograph)."

Please visit http://www.neurometrix.com/pressrelease2.htm for links to the abstracts.

About NeuroMetrix

NeuroMetrix is a medical device company that is establishing and expanding standards of care through the design, development and sale of proprietary products used to help physicians diagnose and treat neuropathies and neurovascular disorders. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. The NC-stat System, the Company's neuropathy diagnostic system, has been on the market since May 1999 and is used in over 4,500 physician's offices and clinics in the United States. Diabetic retinopathy is a common neurovascular complication of diabetes and the leading cause of blindness among working age adults. The Company has exclusive rights in the U.S. physician office arena to market the DigiScope, which is a retinopathy detection system specifically designed for use by primary diabetes care physicians.

Copyright © 2007 NeuroMetrix, Inc. All rights reserved. Privacy Statement NEUROMetrix®, NC-stat®, and onCall™ are trademarks of NeuroMetrix, Inc. Digiscope® is a trademark of Eyetel Imaging Inc. Content on this site is not intended as a substitute for medical advice. You may not copy, republish, redistribute or commercially utilize in any manner any of these materials without prior written permission from NeuroMetrix, Inc.

Source: Business Wire

More News in this Category